anti-CD40L (human), mAb (rec.) (blocking) (hu5c8) (preservative free)
|Synonyms||CD40 Ligand; CD154; Tumor Necrosis Factor Ligand Superfamily Member 5;TNFSF5; Gp39; TRAP|
|Product Type||Recombinant Antibody|
|Immunogen/Antigen||Recombinant human CD40L.|
Flow Cytometry: 1µg/ml
Recognizes and binds human CD40L with an IC50 of 0.845µg/ml. Cross-reacts with canine CD40L.
|Purity Detail||Protein A-affinity purified.|
|Formulation||Liquid. In PBS.|
|Isotype Negative Control|
|Other Product Data||
This antibody is a biosimilar called Ruplizumab (Antova; BG9588) and originally developed by Biogen. Ruplizumab is a CD40 ligand blocker designed for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis, but withdrawn from clinical trials due to side effects.
|Accession Number||UniProt ID P29965|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Handling Advice||Avoid freeze/thaw cycles.|
Stable for at least 1 year after receipt when stored at -20°C.
Stable for at least 3 months after receipt when stored at +4°C.
|Product Specification Sheet|
CD40 Ligand (CD40L), renamed TNFSF5 but now also known as CD154, TRAP and gp39, is a 34-39kDa type II transmembrane glycoprotein, that belongs to the TNF superfamily, and a surface receptor expressed on activated T cells which acts as a costimulatory molecule to trigger immune responses. CD40L binds to CD40, which is essential in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development and germinal center formation. CD40 is constitutively expressed by antigen presenting cells, including dendritic cells, B cells and macrophages. Consistent with its widespread expression on normal cells, CD40 is also expressed on a wide range of tumor cells. CD40L levels are increased in serum and in inflamed tissues of patients with autoimmune diseases.
- Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys: J.V Gobburu, et al.; JPET 286, 925 (1998)
- Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates: A.D. Kirk, et al.; Nat. Med. 5, 686 (1999)
- Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154: N.S. Kenyon, et al.; PNAS 96, 8132 (1999)
- Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154: N.S. Kenyon, et al.; Diabetes 48, 1473 (1999)
- Prolongation of primate cardiac allograft survival by treatment with ANTI-CD40 ligand (CD154) antibody: R.N. Pierson, et al.; Transplantation 68, 1800 (1999)
- Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody: M. Karpusas, et al.; Structure 9, 321 (2001)
- Successful conversion from conventional immunosuppression to anti-CD154 monoclonal antibody costimulatory molecule blockade in rhesus renal allograft recipients: C.S. Cho, et al.; Transplantation 72, 587 (2001)
- Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates: E.A. Elster, et al.; Transplantation 72, 1473 (2001)
- The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus: W. Huang, et al.; Arthr. Rheum. 46, 1554 (2002)
- Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates: H. Xu, et al.; Transplantation 74, 940 (2002)
- A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis: D.T. Boumpas, et al.; Arthr. Rheum. 48, 719 (2003)
- Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions: A.C. Grammer, et al.; J. Clin. Invest. 112, 1506 (2003)
- Human CD34(+) blood cells induce T-cell unresponsiveness to specific alloantigens only under costimulatory blockade: M. Arpinati, et al.; Exp. Hematol. 31, 31 (2003)
- CD154 blockade and donor-specific transfusions in DLA-identical marrow transplantation in dogs conditioned with 1-Gy total body irradiation: C. Jochum, et al.; Biol. Blood Marrow. Transplant. 13, 164 (2007)
- Enhancement of T cell activation by immobilized hu5C8 (anti-CD40L) monoclonal antibody: M. Arpinati, et al.; Eur. J. Haematol. 80, 322 (2008)
- Establishment of long-term tolerance to SRBC in dogs by recombinant canine CTLA4-Ig: S.S. Graves, et al.; Transplantation 88, 317 (2009)